Vaccinating the next generation could make flu season less snot-filled nights — if they hit the public, that is. Trial data this week show that the Pfizer-based flu vaccine performed better than the traditional shot.
On Wednesday, researchers published the results of a phase III trial on the vaccine, sponsored by Pfizer, in the New England Journal of Medicine. The experimental vaccine was more effective at protecting against the flu than the standard vaccine, the researchers found. The vaccine seems to cause more side effects than others, but there is a big concern: it is not certain that it will be approved in the US, given the vaccine technology Mr.
But it is better to hold
The trial involved more than 18,000 healthy volunteers in the US, South Africa and the Philippines. It takes place during the 2022 to 2023 results period. People were randomly assigned to receive one dose of the experimental vaccine, called Modrna, or fluzone, a used flu vaccine made by Sanofi Pasteur. Both vaccines cover the four most common types of influenza that are predicted to be spread that year: influenza viruses and two non-influenza B viruses.
There were fewer confirmed cases of influenza in the Modrna group compared to the control vaccine group (57 vs 87), the study showed. Overall, the Modrna vaccine was 34.5% effective in preventing flu-like illness. The experimental vaccine was also shown to produce a higher antibody response to severe influenza and a similar response to influenza B (Almost all confirmed influenza in the study was caused by influenza A).
“This randomized trial showed that the Modrna vaccine provided both protection against the first episode of laboratory-restricted influenza – recalled between the ages of 18 and 64 years,” the study’s researchers wrote.
That added protection can come with some trade-offs. People given Modrna reported more local reactions (70.1% vs. 43.1%) after their shots, such as pain at the injection site. They were also more likely to report systemic systemic events, such as influenza (5.6% vs 1.7%).
What you find makes sense, because adverse immune reactions are often linked to the immune response you produce. Therefore a strong immune response often causes serious side effects. But while adverse events were more common in those taking modrna, these events tended to be mild or moderately severe. Finally, the study researchers concluded that the adverse events of the two events are the injections.
RRK JR. Wrinkle
All that being said, the biggest problem with Modrna’s approval is not its side effects.
Robert F. Kennedy Jr., the current US secretary of Health and Human Services, and his colleagues were well and truly abused during the second Trump administration. Just this week, for example, the Centers for Disease Control and Prevention changed its website to amplify the myth that it doesn’t cause autism. But as Kennedy and his friends may be able to vaccinate with standard vaccines, they have a strong aversion to MRNA vaccines, a new type of vaccine that was first widely used during the 19 pandemic.
Rfk Jr. He has (wrongly) that the Mrna Covid-19 Shots developed by Pfizer and Moamacana were vaccines “that you had ‘once drunk, for example. Anti-bockogatination advocates also falsely claim that MRNA vaccines are a gene therapy, that they make people pregnant, and that they cause an explosion in turbo cancer.”
This unsupported illegal fear in Mnumyoni has had real world consequences. In May, MoaderA delayed the application for approval of its Flu / Covid-19 vaccine (which also appeared to show greater protection against the flu) after the FDA requested more information. In August, Rfk Jr. he also pulled $500 million in Federal funding for mRNA Vaccine Research and Development.
Contrary to the claims from the vaccination organization MRNA vaccines are worse or more dangerous than other vaccines, this technology can actually strengthen our defense against seasonal flu, not just effectively. Since these vaccines tend to take less time to travel and produce than older types of vaccines, countries can wait longer to select strains that are predicted to circulate during the season. That shortened lag can prevent unexpected froits to cause a mismatch with the vaccine (a bad situation that now happens in winter).
ModernA has stated that it will seek recognition for its lower standing flue. And given these latest results, it will undoubtedly apply for the approval of its Modro principle, too. Usually, both goals seem to have a good chance of being approved. But nothing is normal these days.
